Clinic of General Surgery, Private Goztepe Hospital, Istanbul, Turkey.
Department of General Surgery, Altinbas University Faculty of Medicine Medical Park Bahcelievler Hospital, Istanbul, Turkey.
Biomarkers. 2024 Feb;29(1):30-35. doi: 10.1080/1354750X.2024.2309540. Epub 2024 Feb 5.
The nucleosome assembly protein 1-like 1 (NAP1L1) is suggested to have an oncogenic role in several tumors based on its overexpression. However, its diagnostic and prognostic role in gastric cancer remains unclarified. This study aimed to evaluate the diagnostic and prognostic utility of NAP1L1 in gastric cancer patients.
A total of 85 patients [mean () age: 60.9 (1.6) years, 49.4% were males] with newly-diagnosed gastric cancer and 40 healthy individuals [mean () age: 60.7 (1.7) years, 52.5% were males] were included. Data on patient demographics (age, gender), TNM stages and tumor size, and the serum NAP1L1 levels were recorded.
Serum NAP1L1 levels were significantly higher in gastric cancer patients than in control subjects [12 (9.5-13.8) 1.8 (1.5-2.4) ng/mL, < 0.001]. Also, certain tumor characteristics such as tumor size of >4 <4 cm ( < 0.001), M1 M0 stage ( < 0.001), N2 N0 and N1 stage ( < 0.001), and T4 lower T stage ( < 0.001) were associated with significantly higher serum NAP1L1 levels in gastric cancer patients.
Our findings revealed for the first time that serum levels for NAP1L1 were overexpressed in the gastric cancer, as also correlated with the disease progression. NAP1L1 seems to be a potential biomarker for gastric cancer, providing clinically important information on early diagnosis and risk stratification.
核小体组装蛋白 1 样 1（NAP1L1）基于其过表达被认为在几种肿瘤中具有致癌作用。然而，其在胃癌中的诊断和预后作用仍不清楚。本研究旨在评估 NAP1L1 在胃癌患者中的诊断和预后价值。
共纳入 85 例[平均（）年龄：60.9（1.6）岁，49.4%为男性]初诊胃癌患者和 40 名健康对照者[平均（）年龄：60.7（1.7）岁，52.5%为男性]。记录患者的人口统计学数据（年龄、性别）、TNM 分期和肿瘤大小以及血清 NAP1L1 水平。
胃癌患者的血清 NAP1L1 水平明显高于对照组[12（9.5-13.8）ng/mL 比 1.8（1.5-2.4）ng/mL， < 0.001]。此外，某些肿瘤特征，如肿瘤大小>4 <4cm（ < 0.001）、M1 M0 期（ < 0.001）、N2 N0 和 N1 期（ < 0.001）和 T4 较低的 T 期（ < 0.001）与胃癌患者血清 NAP1L1 水平显著升高相关。
我们的研究结果首次揭示，血清 NAP1L1 水平在胃癌中过度表达，且与疾病进展相关。NAP1L1 似乎是胃癌的一个潜在生物标志物，为早期诊断和风险分层提供了重要的临床信息。
